Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aripiprazole for Pathological Rumination in MDD
NCT06937476Active, not recruiting
- Sponsor
- Central South University
- Start
- May 2025
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, single-blind trial of aripiprazole in major depressive disorder (MDD) and rumination syndrome (4 arms), sponsored by Central South University. Primary endpoint: Ruminative Responses Scale at 8 weeks. Started May 2025; status: active, not recruiting.
02
Drugs
aripiprazole
03
Conditions
major depressive disorder (MDD)rumination syndrome
Beyond the preview
Go deeper on NCT06937476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06937476.